BioLoomics: $8.7 Million Raised To Drive Directed Evolution Of Target Degrading Antibodies Using Human Cells
By Noah Long ● Sep 28, 2023
BioLoomics, the company pioneering the directed evolution of target degrading antibodies using human cells, recently announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs. The round was led by Innovation Endeavors, with participation from Horizons Ventures, TechU Ventures, Boom Capital Ventures, Hummingbird Nomads Fund, Cooley GC&H, BoxOne Ventures and Viswa Colluru (Enveda founder).